Nacuity Pharmaceuticals, Inc. is a clinical stage biotech focused on treatment of ocular oxidative stress.
Initial focus to develop a breakthrough treatment for retinitis pigmentosa (RP).
Technology based on studies from the laboratory of Dr. Peter Campochiaro, Wilmer Eye Institute, involving oxidative stress in the retina.
Our work in RP has led us to also pursue other ocular diseases involving oxidative stress.